Boston Scientific's disappointing 2025 earnings report, marked by slower market growth and heightened competition from rivals like Johnson & Johnson, has led the company to revise its 2026 organic revenue guidance downward. Despite these challenges, the global drug-eluting stents market is expected to grow to USD 14.5 billion by 2034, potentially benefiting Boston Scientific in the long term. The company recently completed a $14.5 billion acquisition of Penumbra, aiming to strengthen its market position amidst negative investor sentiment and price target reductions. Improved market conditions could emerge if geopolitical tensions in the Middle East stabilize.
“Major Market Drivers: Growing incidence of cardiovascular conditions like irregular heart rhythms and heart attacks is boosting market demand. Competitive Landscape: Key players include Abbott, B. Braun SE, Biosensors International, Biotronik, Boston Scientific, Cook Medical...”
“The global drug-eluting stents market size, valued at USD 9.2 Billion in 2025, is projected to reach USD 14.5 Billion by 2034, growing at a CAGR of 5.03% from 2026 to 2034.”
“In 2026, dealmaking activity has fallen somewhat short of expectations. At the J.P. Morgan Healthcare conference in January 2026, Boston Scientific’s $14.5bn acquisition of Penumbra was the standout medtech megadeal.”
“The narrative around medtech, however, has continued to be negative, in that it's a sector that's definitely out of favour with investors.”
“Ultimately, and as the Middle East situation hopefully resolves, and potentially more AI comes into medtech... we will again begin to see medtech gravitate more towards the median, maybe even to a premium.”
“On February 4, 2026, Boston Scientific reported fourth quarter and full year 2025 results, including a disappointment in U.S. Electrophysiology sales, and issued fiscal 2026 guidance — including for the first half of 2026 — that fell below expectations.”
“The Company attributed the results to slower than expected market growth and increased competition, despite prior statements describing the EP business as 'growing' and asserting it had 'a very good understanding of what competition we will face and in what time frame.'”
“The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects.”
“Truist cut the price target on Boston Scientific Corporation (NYSE:BSX) to $90 from $92 on April 15 and maintained a Buy rating on the shares.”
“Boston Scientific | 26 | 0.19 | 3841 | Medical Equipment | Health | BSX”
“Boston Scientific · had · adjusted EPS · $0.80”
“Boston Scientific · maintained · operating margin · 28.0%”
